Residual Cardiovascular Risk Drug Pipeline — PatSnap Eureka
Residual Cardiovascular Risk: ANGPTL3, LPA & PCSK9 Silencing Strategies
Despite optimized statin therapy, a substantial proportion of high-risk patients continue to experience recurrent MACE — driving a new wave of patent activity across monoclonal antibodies, RNAi, antisense oligonucleotides, and base editing targeting PCSK9, ANGPTL3, and LPA.
Patent Filings by Assignee
Regeneron leads with 12+ filings; Verve Therapeutics dominates the base editing space with 4 filings across PCSK9 and ANGPTL3.
Three Lipid-Regulatory Targets Driving the Next Wave of CV Innovation
Cardiovascular disease remains the leading cause of global mortality. Despite optimized statin therapy, a substantial proportion of patients experience recurrent major adverse cardiovascular events (MACE) — a phenomenon termed "residual cardiovascular risk." Multiple patents explicitly note that "a significant number of high-risk patients cannot achieve recommended LDL-C target levels" and that "the majority of CV events are not actually prevented."
The patent and literature landscape from 2010 through 2026 reveals three principal molecular targets: PCSK9, the dominant target with over 30 distinct filings; ANGPTL3, a liver-expressed gene targeted via base editing by Verve Therapeutics; and LPA, encoding apolipoprotein(a) — a component of Lp(a) particles identified as an independent cardiovascular risk factor with no approved pharmacological treatment at the time of filing.
According to a WIPO-tracked patent landscape, therapeutic approaches span monoclonal antibodies, RNA interference, antisense oligonucleotides (ASOs), and emerging base-editing technologies. The PatSnap life sciences platform captures innovation signals across all four modalities for these targets. For broader context on cardiovascular disease burden, see data from the World Health Organization.
A key finding across retrieved filings is the convergence on post-ACS patients as the primary indication, with the 12-month post-ACS window identified as the highest-risk, highest-benefit treatment period. Regeneron's filings further note that approximately 10% of patients who previously had MACE experience cardiovascular death, recurrent MI, or stroke within one year — establishing the clinical unmet need for more durable or potent interventions.
Four Distinct Approaches to PCSK9, ANGPTL3, and LPA Silencing
The dataset spans monoclonal antibodies through to next-generation genomic base editing, each offering distinct durability, delivery, and IP positioning profiles.
Anti-PCSK9 Monoclonal Antibodies
The most heavily represented modality. Multiple assignees — Regeneron, Sanofi, Amgen, Pfizer, and AstraZeneca — hold overlapping global patent positions covering anti-PCSK9 antibodies. The mechanism involves direct binding to circulating PCSK9 protein, blocking its interaction with the LDL receptor and increasing hepatic LDL-C clearance. Alirocumab (mAb316P, Sanofi/Regeneron) and evolocumab (Amgen) are the principal antibodies described, with patent claims spanning CDR sequences, dosing regimens, and specific clinical indications. Dosing regimens include subcutaneous administration at 75–150 mg every two to four weeks.
LDL-C reduction: 40–60% from baseline on statin backgroundRNA Interference (RNAi) Targeting PCSK9 and LPA
Alnylam Pharmaceuticals (PCSK9) and Amgen (LPA) hold patent families covering double-stranded RNAi agents formulated for hepatic delivery. Guide strand-directed mRNA cleavage leads to degradation of the target mRNA and suppression of protein synthesis. Alnylam's PCSK9 RNAi agent features a loading phase (200–600 mg fixed dose) followed by quarterly maintenance dosing at 25–100 mg — a dosing frequency advantage over monthly antibody administration. Novartis filings note that monoclonal antibodies have "short duration of action, which may lead to heavy dosing and economic burden." Non-human primate data cited.
Quarterly maintenance dosing vs. monthly for mAbsAntisense Oligonucleotides (ASOs) Targeting PCSK9
Santaris Pharma (now Roche Innovation Center Copenhagen) disclosed locked nucleic acid (LNA)-based RNA antagonist oligomeric compounds hybridizable with PCSK9-encoding target nucleic acid. The filing explicitly notes synergistic activity between PCSK9 inhibition and statin therapy via complementary LDLR upregulation mechanisms. A related filing from Sirna Therapeutics (now Merck) describes siNA, siRNA, dsRNA, miRNA, and shRNA molecules targeting PCSK9, including lipid nanoparticle (LNP) formulations. These represent early-stage filings from 2010.
Synergistic LDLR upregulation with statin co-therapyBase Editing of PCSK9 and ANGPTL3
The most technically distinctive modality. Verve Therapeutics describes in vivo hepatic base editing using adenine base editor (ABE8.8) fusion proteins delivered via lipid nanoparticles. Guide RNAs direct the base editor to protospacers on either the PCSK9 or ANGPTL3 gene locus, creating durable, heritable silencing in hepatocytes. Non-human primate (cynomolgus macaque) experiments used LNP doses of 0.5–3 mg/kg IV, with hepatic PCSK9 base editing in at least 35% of hepatocytes at ≥0.05 mg/kg total dose. Dual-gene editing of PCSK9 + ANGPTL3 is co-disclosed as a combination strategy for ASCVD.
≥35% hepatocytes edited in NHP at ≥0.05 mg/kg (Verve)Patent Landscape Data: Targets, Modalities & Development Stage
Key quantitative signals extracted from the 2010–2026 patent and literature dataset via PatSnap Eureka.
Therapeutic Modalities by Development Stage
Anti-PCSK9 mAbs carry the strongest clinical evidence; base editing is at preclinical/IND-enabling stage with NHP data from Verve Therapeutics.
Dosing Frequency: mAb vs. RNAi for PCSK9 Inhibition
RNAi quarterly maintenance dosing represents a significant convenience advantage over monthly subcutaneous mAb administration, per Alnylam and Novartis filings.
IP Density by Target: PCSK9 vs. ANGPTL3 vs. LPA
PCSK9 is the most crowded IP space with 30+ filings across 6+ assignees. ANGPTL3 and LPA are addressed by single assignees each, representing lower IP density and potentially more defensible positions.
Combination Strategies in the Pipeline
From established statin + mAb combinations to emerging dual-gene base editing, the pipeline is moving toward multi-target residual risk reduction.
Key Patent Holders Across PCSK9, ANGPTL3 & LPA
Patent activity is strongly dominated by large-cap pharmaceutical companies. Regeneron leads with 12+ filings; Verve Therapeutics owns the base editing space.
| Assignee | Primary Target(s) | Modality | Key Jurisdictions | Stage Signal |
|---|---|---|---|---|
| Regeneron Pharmaceuticals | PCSK9, Lp(a) | mAb (alirocumab) | MX, CA, WO, JP, TW | Clinical/Approved |
| Sanofi Biotechnology | PCSK9 | mAb (alirocumab) | JP, CN, KR, WO | Clinical/Approved |
| Amgen Inc. | PCSK9, LPA | mAb (evolocumab), RNAi | AU, JP, BR | Clinical/Approved |
| Alnylam Pharmaceuticals | PCSK9 | RNAi | JP (3 families) | Clinical-Stage Signals |
Track Competitor Patent Activity Across All Three Targets
PatSnap Eureka monitors new filings, assignee moves, and jurisdiction expansions in real time.
IP Strategy Signals for PCSK9, ANGPTL3 & LPA
Key strategic findings for R&D teams, IP counsel, and business development professionals navigating this pipeline.
PCSK9 IP Is Maturing and Crowded
The dataset contains over 30 PCSK9-focused patent filings across at least six major assignees and eight jurisdictions. IP strategy for new entrants should focus on differentiated modalities (base editing, RNAi) or specific indications — such as patients intolerant to statins or those with genetic PCSK9 gain-of-function mutations — rather than competing directly on antibody CDR sequences.
RNA Silencing Represents the Durability Advantage
Alnylam's quarterly RNAi dosing and Novartis's PCSK9 RNAi programs explicitly position RNA-based approaches as superior to monoclonal antibodies on durability and dosing convenience. Developers in this space should expect regulatory and commercial competition from at least two well-resourced organizations. The PatSnap analytics platform can map the competitive RNAi landscape.
ANGPTL3 and LPA Are Undercrowded
In this dataset, ANGPTL3 is addressed exclusively by Verve Therapeutics (base editing context) and LPA exclusively by Amgen (RNAi context). These targets represent lower IP density and potentially more defensible patent positions for organizations with capabilities in genomic editing or RNA therapeutics. For life sciences IP strategy, the PatSnap life sciences solution provides deep target-level analysis.
Base Editing: Highest Risk, Highest Reward
Verve Therapeutics' non-human primate data demonstrate durable hepatic editing, but liver safety (AST/ALT monitoring) is explicitly tracked, signaling that hepatotoxicity remains a key regulatory concern. IP and clinical development in this area require robust safety packages prior to clinical advancement. LNP doses of 0.5–3 mg/kg in cynomolgus macaques are referenced as IND-enabling data.
From NHP Studies to Approved Indications: Where the Pipeline Stands
Retrieved results contain several signals of clinical translation, concentrated in the PCSK9 antibody space. Multiple Regeneron and Sanofi patent filings explicitly reference clinical trial data, including alirocumab's demonstrated ability to lower LDL-C by at least 40–60% and reduce MACE in post-ACS patients.
The ODYSSEY OUTCOMES trial is referenced in a MedImmune/AstraZeneca filing, which notes a 9.5% residual cardiovascular risk over 2.8 years despite PCSK9 inhibition plus statin therapy — explicitly framing the need for additional targets. According to the NIH, cardiovascular disease research investment continues to expand precisely because of this persistent residual risk burden.
Alnylam's PCSK9 RNAi filings describe a loading/maintenance dosing regimen (200–600 mg loading, 25–100 mg quarterly maintenance) consistent with clinical development stage optimization. Verve Therapeutics' base editing filings reference non-human primate studies as IND-enabling data, with long-term liver function monitoring data presented.
No retrieved records describe completed Phase III trials or regulatory approvals for ANGPTL3 base editing, LPA RNAi, or PCSK9 RNAi agents. The antibody modality contains the strongest clinical evidence signals. For regulatory context, see the FDA's guidance on novel lipid-lowering therapies. The PatSnap customer success stories include pharma teams using Eureka to track exactly these pipeline transitions.
Regeneron's filings on genome-based methods further note that approximately 10% of patients who previously had MACE experience cardiovascular death, recurrent MI, or stroke within one year — establishing the clinical unmet need for more durable or potent interventions beyond current standard of care.
- Anti-PCSK9 mAbs (alirocumab, evolocumab): strongest clinical evidence, approved indications described
- PCSK9 RNAi (Alnylam): loading/maintenance regimen consistent with clinical development optimization
- LPA-targeted RNAi (Amgen): specific dosage regimens described, suggesting translational readiness
- PCSK9 + ANGPTL3 base editing (Verve): NHP IND-enabling data; hepatotoxicity monitoring ongoing
- No Phase III data or approvals for ANGPTL3 base editing, LPA RNAi, or PCSK9 RNAi in retrieved records
Residual Cardiovascular Risk Drug Pipeline — key questions answered
Residual cardiovascular risk refers to the substantial proportion of patients who experience recurrent major adverse cardiovascular events (MACE) despite optimized statin therapy. Multiple patents explicitly note that a significant number of high-risk patients cannot achieve recommended LDL-C target levels and that the majority of CV events are not actually prevented, leaving patients with substantial residual risk.
The three principal molecular targets are PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9), ANGPTL3 (Angiopoietin-Like Protein 3), and LPA (Apolipoprotein(a) / Lipoprotein(a)). PCSK9 is the dominant target with over 30 distinct patent filings. ANGPTL3 is addressed by Verve Therapeutics via base editing. LPA is targeted by Amgen via RNAi constructs.
PCSK9 is being targeted at three levels: at the protein level via monoclonal antibodies (alirocumab, evolocumab), at the mRNA level via RNA interference (RNAi) and antisense oligonucleotides (ASOs), and at the genomic level via base editing using adenine base editor (ABE8.8) fusion proteins delivered via lipid nanoparticles.
Retrieved patents describe LDL-C reductions of at least 40–60% from baseline on top of statin therapy for anti-PCSK9 monoclonal antibodies such as alirocumab and evolocumab. Amgen's atherosclerosis combination patent describes LDL-C reduction to 30 mg/dL via evolocumab plus statin background, with evidence of atherosclerosis regression and reduced cardiovascular event risk.
Alnylam's PCSK9 RNAi agent is described with a dosing regimen comprising a loading phase (200–600 mg fixed dose) followed by maintenance quarterly dosing at 25–100 mg — a dosing frequency advantage over monthly antibody administration. Novartis filings also note that monoclonal antibodies have short duration of action, which may lead to heavy dosing and economic burden.
Verve Therapeutics describes in vivo hepatic base editing using adenine base editor (ABE8.8) fusion proteins delivered via lipid nanoparticles. Non-human primate (cynomolgus macaque) experiments with LNP doses of 0.5–3 mg/kg administered intravenously showed hepatic PCSK9 base editing occurring in at least 35% of hepatocytes. The ANGPTL3 filing co-discloses combination editing of both PCSK9 and ANGPTL3 as a strategy for treating ASCVD, representing the most advanced genomic editing approach in this dataset.
Still have questions? Let PatSnap Eureka search the patent literature for you.
Ask Eureka About the CV PipelineAccelerate Your Residual Cardiovascular Risk Research
Join 18,000+ innovators already using PatSnap Eureka to map drug pipelines, track assignee IP moves, and identify undercrowded target opportunities across PCSK9, ANGPTL3, and LPA.
References
- Antigen Binding Proteins to Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9)
- Use of PCSK9 inhibitors to reduce cardiovascular risk
- Methods for reducing cardiovascular risk
- Genome-based methods for reducing cardiovascular risk
- Methods and compositions for treating proprotein convertase subtilisin/kexin (PCSK9) gene-related disorders
- Methods and compositions for treating proprotein convertase subtilisin/kexin (PCSK9) gene-associated disorders
- Methods and compositions for treating proprotein convertase subtilisin/kexin (PCSK9) gene-associated disorder
- Methods for treating cardiovascular atherosclerotic disease with RNAi constructs targeting LPA
- Base editing of PCSK9 and methods of using it to treat disease
- Base editing of ANGPTL3 and methods of using the same for treatment of disease
- Base editing of PCSK9 and methods of using the same for treatment of disease
- Base Editing of ANGPTL3 and Methods of Using It to Treat Disease
- RNA antagonist compounds for modulating PCSK9
- RNA interference-mediated inhibition of proprotein convertase subtilisin kexin 9 (PCSK9) gene expression using a small interfering nucleic acid (siNA)
- Methods for preventing cardiovascular events by reducing PCSK9 protein
- Combination Therapies for Cardiovascular Disease
- Combination therapy for cardiovascular diseases
- Combined treatment of atherosclerosis, including atherosclerotic cardiovascular disease
- PCSK9 inhibitors and methods of treatment using same
- Optimized methods for delivering dsRNA targeting the PCSK9 gene
- World Health Organization — Cardiovascular Disease Data
- National Institutes of Health — Cardiovascular Research
- U.S. Food and Drug Administration — Novel Lipid-Lowering Therapy Guidance
- World Intellectual Property Organization — Patent Landscape Reports
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This page represents a snapshot of innovation signals within the retrieved dataset only and should not be interpreted as a comprehensive view of the full field, clinical pipeline, or regulatory landscape.
PatSnap Eureka searches patents and research to answer instantly.